Literature DB >> 19561811

Treatment of melanoma.

Claus Garbe1, Patrick Terheyden, Ulrich Keilholz, Oliver Kölbl, Axel Hauschild.   

Abstract

INTRODUCTION: The incidence of melanoma has increased fivefold during the past three decades. Melanoma can no longer be classified as rare; rather, it is now one of the more frequent tumors.
METHODS: Recommendations for the diagnosis and treatment of melanoma are laid out in the interdisciplinary S2 guidelines of the German Cancer Society, upon which the present review is based. The goal of this article is to present the clinical core recommendations for treatment in all disease stages.
RESULTS: The operative management of primary melanoma usually takes place in two steps. A complete excisional biopsy with a safety margin of about 2 mm is performed in order to establish the histopathological diagnosis. Definitive surgical excision is performed with a safety margin of 1 cm in tumors up to 2 mm thick, 2 cm in thicker tumors. In tumors more than 1 mm thick, sentinel lymph node biopsy should be performed to aid in tumor staging. Radiotherapy is indicated in inoperable tumors of all stages. Adjuvant immunotherapy with interferon alpha is recommended in tumors of thickness >2 mm and in locoregional metastasis. If distant metastasis is present and R0 surgery is not an option, the treatment should primarily comprise monochemotherapy or alternatively the patient should be enrolled in a clinical trial.
CONCLUSION: The recommendations presented here are based predominantly on the results of prospective randomized trials.

Entities:  

Keywords:  adjuvant therapy; cancer treatment; radiotherapy; skin cancer; surgery

Year:  2008        PMID: 19561811      PMCID: PMC2689638          DOI: 10.3238/arztebl.2008.0845

Source DB:  PubMed          Journal:  Dtsch Arztebl Int        ISSN: 1866-0452            Impact factor:   5.594


  23 in total

Review 1.  Melanoma.

Authors:  Arlo J Miller; Martin C Mihm
Journal:  N Engl J Med       Date:  2006-07-06       Impact factor: 91.245

2.  A prospective phase II study of adjuvant postoperative radiation therapy following nodal surgery in malignant melanoma-Trans Tasman Radiation Oncology Group (TROG) Study 96.06.

Authors:  Bryan H Burmeister; B Mark Smithers; Elizabeth Burmeister; Kathryn Baumann; Sidney Davis; Hedley Krawitz; Carol Johnson; Nigel Spry
Journal:  Radiother Oncol       Date:  2006-10-24       Impact factor: 6.280

3.  Control of excisional margins by conventional histopathological techniques in the treatment of skin tumours. An alternative to Mohs' technique.

Authors:  H Breuninger; G Schaumburg-Lever
Journal:  J Pathol       Date:  1988-02       Impact factor: 7.996

4.  Technical details of intraoperative lymphatic mapping for early stage melanoma.

Authors:  D L Morton; D R Wen; J H Wong; J S Economou; L A Cagle; F K Storm; L J Foshag; A J Cochran
Journal:  Arch Surg       Date:  1992-04

5.  Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients.

Authors:  J E Gershenwald; W Thompson; P F Mansfield; J E Lee; M I Colome; C H Tseng; J J Lee; C M Balch; D S Reintgen; M I Ross
Journal:  J Clin Oncol       Date:  1999-03       Impact factor: 44.544

6.  Sentinel-node biopsy or nodal observation in melanoma.

Authors:  Donald L Morton; John F Thompson; Alistair J Cochran; Nicola Mozzillo; Robert Elashoff; Richard Essner; Omgo E Nieweg; Daniel F Roses; Harald J Hoekstra; Constantine P Karakousis; Douglas S Reintgen; Brendon J Coventry; Edwin C Glass; He-Jing Wang
Journal:  N Engl J Med       Date:  2006-09-28       Impact factor: 91.245

7.  [Locally recurrent and metastatic malignant melanoma. Long-term results and prognostic factors after percutaneous radiotherapy].

Authors:  M H Seegenschmiedt; L Keilholz; A Pieritz; A Altendorf-Hofmann; A Urban; H Schell; W Hohenberger; R Sauer
Journal:  Strahlenther Onkol       Date:  1999-09       Impact factor: 3.621

Review 8.  Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion.

Authors:  Axel Hauschild; Helen Gogas; Ahmad Tarhini; Mark R Middleton; Alessandro Testori; Brigitte Dréno; John M Kirkwood
Journal:  Cancer       Date:  2008-03-01       Impact factor: 6.860

9.  A higher radiotherapy dose is associated with more durable palliation and longer survival in patients with metastatic melanoma.

Authors:  Kenneth R Olivier; Steven E Schild; Christopher G Morris; Paul D Brown; Svetomir N Markovic
Journal:  Cancer       Date:  2007-10-15       Impact factor: 6.860

10.  Evidence and interdisciplinary consensus-based German guidelines: surgical treatment and radiotherapy of melanoma.

Authors:  Claus Garbe; Axel Hauschild; Matthias Volkenandt; Dirk Schadendorf; Wilhelm Stolz; Uwe Reinhold; Rolf-Dieter Kortmann; Christoph Kettelhack; Bernhard Frerich; Ulrich Keilholz; Reinhard Dummer; Günther Sebastian; Wolfgang Tilgen; Gerold Schuler; Andreas Mackensen; Roland Kaufmann
Journal:  Melanoma Res       Date:  2008-02       Impact factor: 3.599

View more
  6 in total

1.  The Application of ATR Kinase Inhibitor AZD6738 in Combination with Radiotherapy for the Treatment of Melanoma.

Authors:  Maryam Talebpoor; Ali Neshasteh-Riz; Fereshteh Koosha; Samira Eynali
Journal:  J Biomed Phys Eng       Date:  2022-06-01

2.  Calcaneal melanoma; our rare case and review of the literature.

Authors:  Karaiskos Ioannis; Palla Victoria; Pateras Ioannis; Stamatakos Michael
Journal:  Indian J Surg       Date:  2010-12-03       Impact factor: 0.656

3.  Downregulation of tumor growth and invasion by redox-active nanoparticles.

Authors:  Lirija Alili; Maren Sack; Claudia von Montfort; Shailendra Giri; Soumen Das; Kate S Carroll; Klaus Zanger; Sudipta Seal; Peter Brenneisen
Journal:  Antioxid Redox Signal       Date:  2013-01-24       Impact factor: 8.401

4.  Psychosocial Care Needs of Melanoma Survivors: Are They Being Met?

Authors:  Sabine Fischbeck; Barbara H Imruck; Maria Blettner; Veronika Weyer; Harald Binder; Sylke R Zeissig; Katharina Emrich; Peter Friedrich-Mai; Manfred E Beutel
Journal:  PLoS One       Date:  2015-08-21       Impact factor: 3.240

5.  Economic burden of toxicities associated with treating metastatic melanoma in eight countries.

Authors:  Elizabeth Wehler; Zhongyun Zhao; S Pinar Bilir; Julie Munakata; Beth Barber
Journal:  Eur J Health Econ       Date:  2015-12-31

6.  Comparison of the influence of photodynamic reaction on the Me45 and MEWO cell lines in vitro.

Authors:  Anna Choromańska; Jolanta Saczko; Julita Kulbacka; Iwona Kamińska; Nina Skołucka; Michał Majkowski
Journal:  Contemp Oncol (Pozn)       Date:  2012-07-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.